Zydus Lifesciences on Monday said it has received approval from the US health regulator to market a drug for the treatment of irritable bowel syndrome with diarrhoea in adults.
The company has received tentative approval from the US Food and Drug Administration (USFDA) for Rifaximin Tablets (550 mg), the drug manufacturing firm said in a regulatory filing.
Rifaximin tablets are indicated for the treatment of irritable bowel syndrome with diarrhoea ( IBS-D) in adults.
As per the IQVIA MAT March sales data, Rifaximin tablets had an annual sales of USD 2,672.9 million in the US.
Shares of Zydus Lifesciences were trading at Rs 926.05 apiece, 0.41 per cent down from previous close, on BSE.
The company has received tentative approval from the US Food and Drug Administration (USFDA) for Rifaximin Tablets (550 mg), the drug manufacturing firm said in a regulatory filing.
Rifaximin tablets are indicated for the treatment of irritable bowel syndrome with diarrhoea ( IBS-D) in adults.
As per the IQVIA MAT March sales data, Rifaximin tablets had an annual sales of USD 2,672.9 million in the US.
Shares of Zydus Lifesciences were trading at Rs 926.05 apiece, 0.41 per cent down from previous close, on BSE.
You may also like
ACB summons Manish Sisodia and Satyendar Jain over Rs 2,000 crore school construction corruption probe
COVID Surge In UP: Lucknow Reports Fifth Case Amid Testing Gaps, Lax Protocols At Government Hospitals
Qurbani Controversy Heats Up: Muslim Leaders Condemn BJP's Seasonal Morality Ahead Of Eid ul Azha
'Aced audition, kept two years in waiting': TV star Siddharth Nigam's mom shares how actor was ditched for star kids for debut film
UK cities may need to adopt digital graveyards as burial spaces dwindle
